Serina Therapeutics, Inc. (SER) AMEX
1.93
-0.03(-1.53%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.93
-0.03(-1.53%)
Currency In USD
| Previous Close | 1.96 |
| Open | 1.98 |
| Day High | 1.98 |
| Day Low | 1.91 |
| 52-Week High | 7.92 |
| 52-Week Low | 1.22 |
| Volume | 167,945 |
| Average Volume | 4.69M |
| Market Cap | 19.3M |
| PE | -1.01 |
| EPS | -1.91 |
| Moving Average 50 Days | 1.98 |
| Moving Average 200 Days | 3.82 |
| Change | -0.03 |
Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease
GlobeNewswire Inc.
Feb 24, 2026 9:05 PM GMT
- Blinded evaluation of safety and tolerability data by the Safety Monitoring Committee from Cohort 1 and advancement to Cohort 2 is expected in 3Q 2026 – - Advancement reflects continued execution of capital-efficient development strategy leveraging
Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease
GlobeNewswire Inc.
Feb 19, 2026 11:00 AM GMT
- First patient successfully enrolled in global registrational study in Australia - Operational presence in Australia positions Serina to advance enrollment in Cohort 1- Company remains on track for first patient dosing in the first quarter of 2026
Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event
GlobeNewswire Inc.
Feb 03, 2026 11:00 AM GMT
“Navigating the New FDA Era: 2026 Strategic Priorities and the Future of Life Sciences" Featuring Serina Therapeutics’ CEO - Wednesday, February 4, 2026 Hear how FDA initiatives in 2026 may impact drug development timelines, review processes, and in